Product: Ponatinib
Headline: Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells
Author: Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Kazuma Ohyashiki
Product: TAE684, crizotinib & AZD6244
Headline: Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
Author: J Tanizaki, I Okamoto, K Takezawa, K Sakai, K Azuma, K Kuwata, H Yamaguchi, E Hatashita, K Nishio, P A Janne and K Nakagawa
Product: vandetanib
Headline: Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
Author: J Tanizaki, I Okamoto, K Sakai and K Nakagawa
Product: CCI779
Headline: mTOR-targeted therapy: Differential perturbation to mitochondrial membrane potential and permeability transition pore plays a role in therapeutic response...
Author: Jae Eun Kimb, Qun Hea, Yaqing Chena, Celine Shib, Ker Yua, b
Product: Perifosine
Headline: Perifosine sensitizes UVB-induced apoptosis in skin cells: New implication of skin cancer prevention?
Author: Chao Ji, Yan-li Yang, Zhi Yang, Ying Tu, Lei Cheng, Bin Chen, Ji-ping Xia, Wei-ling Sun, Zhong-lan Su, Li He, Zhi-gang Bi
Product: BEZ235 & AZD6244
Headline: Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
Author: Wataru Okamoto, Isamu Okamoto, Tokuzo Arao, Kiyoko Kuwata, Erina Hatashita, Haruka Yamaguchi, Kazuko Sakai, Kazuyoshi Yanagihara, Kazuto Nishio, and Kazuhiko Nakagawa
Product: TAE684
Headline: Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer
Author: Ken Takezawa, Isamu Okamoto, Kazuto Nishio, Pasi A. J?nne, and Kazuhiko Nakagawa
Product: Halofuginone
Headline: Therapeutic effect of Halofuginone on ITP mice by regulating the differentiation of Th cell subsets
Author: Chengqiang Jin, 1, Yanxia Jia, Chengying Jin, Haixin Dong, Panpan Cheng, Jianwei Zhou, Yu Wang, Biying Zheng, Fang Liu
Product: Sorafenib
Headline: 1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib
Author: Jia-Hui Chu, Cui-Rong Zhao, Zhi-Yu Song, Rui-Qi Wang, Yi-Zhuo Qin, Wen-Bao Li, Xian-Jun Qu